ARTICLE | Clinical News
Teplizumab: Phase III started
June 22, 2009 7:00 AM UTC
The partners began the double-blind, placebo-controlled, international Phase III Protege Encore trial to evaluate 3 dosages of IV teplizumab in about 400 patients. Eli Lilly has exclusive, worldwide r...